Novartis In Line For Ofatumumab MS Approval In June
Will Rival Roche's Ocrevus
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.